CL2016003179A1 - El control efectivo y eficaz del fosfato sérico para una osificación óptima - Google Patents

El control efectivo y eficaz del fosfato sérico para una osificación óptima

Info

Publication number
CL2016003179A1
CL2016003179A1 CL2016003179A CL2016003179A CL2016003179A1 CL 2016003179 A1 CL2016003179 A1 CL 2016003179A1 CL 2016003179 A CL2016003179 A CL 2016003179A CL 2016003179 A CL2016003179 A CL 2016003179A CL 2016003179 A1 CL2016003179 A1 CL 2016003179A1
Authority
CL
Chile
Prior art keywords
effective
ossification
optimal
serum phosphate
effective control
Prior art date
Application number
CL2016003179A
Other languages
English (en)
Inventor
Emil Kakkis
Martin Javier San
Tomohiro Sudo
Original Assignee
Ultragenyx Pharmaceutical Inc
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc, Kyowa Hakko Kirin Co Ltd filed Critical Ultragenyx Pharmaceutical Inc
Publication of CL2016003179A1 publication Critical patent/CL2016003179A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001132—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA COMPOSICIONES Y MÉTODOS PARA TRATAR UN TRASTORNO HIPOFOSFATÉMICO, TAL COMO HIPOFOSFATEMIA LIGADA AL CROMOSOMA X (XLH). EL MÉTODO CONLLEVA ADMINISTRAR A UN SUJETO UNA COMPOSICIÓN FARMACÉUTICA QUE CONTIENE UN LIGANDO ANTI-FGF23, DONDE EL RÉGIMEN DE COSIFICACIÓN DEL FÁRMACO SE DISEÑA PARA ALCANZAR UN CONTROL EFECTIVO Y EFICAZ DE LA ACTIVIDAD DE FGF23.</p>
CL2016003179A 2014-06-09 2016-12-09 El control efectivo y eficaz del fosfato sérico para una osificación óptima CL2016003179A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462009474P 2014-06-09 2014-06-09

Publications (1)

Publication Number Publication Date
CL2016003179A1 true CL2016003179A1 (es) 2017-11-03

Family

ID=54769049

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003179A CL2016003179A1 (es) 2014-06-09 2016-12-09 El control efectivo y eficaz del fosfato sérico para una osificación óptima

Country Status (23)

Country Link
US (4) US10639360B2 (es)
EP (2) EP3845245A1 (es)
JP (2) JP6808493B2 (es)
KR (2) KR20210099180A (es)
CN (1) CN106604743A (es)
AR (1) AR100689A1 (es)
AU (1) AU2015275128C1 (es)
BR (2) BR122023023102A2 (es)
CA (1) CA2949234C (es)
CL (1) CL2016003179A1 (es)
CY (1) CY1124328T1 (es)
DK (1) DK3151859T3 (es)
ES (1) ES2851674T3 (es)
HR (1) HRP20210250T1 (es)
HU (1) HUE053271T2 (es)
LT (1) LT3151859T (es)
MX (2) MX2016016296A (es)
PE (1) PE20170248A1 (es)
PL (1) PL3151859T3 (es)
PT (1) PT3151859T (es)
RS (1) RS61443B1 (es)
SI (1) SI3151859T1 (es)
WO (1) WO2015191312A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3404102T (pt) 2004-04-21 2021-09-16 Alexion Pharma Inc Conjugados de entrega óssea e método de usar os mesmos para direcionar as proteínas ao osso
EP3845245A1 (en) 2014-06-09 2021-07-07 Ultragenyx Pharmaceutical Inc. The effective and efficient control of serum phosphate for optimal bone formation
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
WO2016090251A1 (en) 2014-12-05 2016-06-09 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
WO2017031114A1 (en) 2015-08-17 2017-02-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
CN106709662B (zh) * 2016-12-30 2021-07-02 山东鲁能软件技术有限公司 一种电力设备运行工况划分方法
CA3057502A1 (en) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
AU2005202100A1 (en) 1999-05-11 2005-06-09 Ortho-Mcneil Pharmaceutical, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
NZ522045A (en) 2000-03-30 2007-05-31 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
AU2001273323B2 (en) 2000-07-19 2005-11-10 Advanced Research & Technology Institute Novel fibroblast growth factor (FGF23) and methods for use
TWI224620B (en) 2000-08-11 2004-12-01 Kirin Brewery Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
ATE441666T1 (de) * 2001-12-28 2009-09-15 Kyowa Hakko Kirin Co Ltd Antikírper gegen den fibroblastenwachstumsfaktor 23
US8158725B2 (en) 2005-08-22 2012-04-17 Bridgestone Corporation Functionalized polymers and tires therefrom
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
EP3845245A1 (en) 2014-06-09 2021-07-07 Ultragenyx Pharmaceutical Inc. The effective and efficient control of serum phosphate for optimal bone formation

Also Published As

Publication number Publication date
JP2017524656A (ja) 2017-08-31
MX2021003740A (es) 2021-05-27
US20240115683A1 (en) 2024-04-11
DK3151859T3 (da) 2021-02-15
PT3151859T (pt) 2021-02-03
AR100689A1 (es) 2016-10-26
AU2015275128A1 (en) 2016-12-08
KR20210099180A (ko) 2021-08-11
JP6808493B2 (ja) 2021-01-06
RS61443B1 (sr) 2021-03-31
EP3845245A1 (en) 2021-07-07
EP3151859B1 (en) 2020-11-25
US11202822B2 (en) 2021-12-21
JP6993490B2 (ja) 2022-02-03
AU2015275128C1 (en) 2020-02-13
EP3151859A4 (en) 2018-01-17
US20150353633A1 (en) 2015-12-10
ES2851674T3 (es) 2021-09-08
MX2016016296A (es) 2017-10-12
SI3151859T1 (sl) 2021-06-30
EP3151859A1 (en) 2017-04-12
US20220133871A1 (en) 2022-05-05
US11771748B2 (en) 2023-10-03
LT3151859T (lt) 2021-03-25
BR112016028567A2 (pt) 2018-01-30
US20200330575A1 (en) 2020-10-22
JP2021050226A (ja) 2021-04-01
AU2015275128B2 (en) 2019-10-31
WO2015191312A1 (en) 2015-12-17
KR20170013993A (ko) 2017-02-07
CA2949234A1 (en) 2015-12-17
HUE053271T2 (hu) 2021-06-28
PE20170248A1 (es) 2017-04-14
PL3151859T3 (pl) 2021-07-26
CA2949234C (en) 2022-03-22
US10639360B2 (en) 2020-05-05
BR122023023102A2 (pt) 2024-03-05
CY1124328T1 (el) 2022-07-22
HRP20210250T1 (hr) 2021-04-02
CN106604743A (zh) 2017-04-26

Similar Documents

Publication Publication Date Title
CL2016003179A1 (es) El control efectivo y eficaz del fosfato sérico para una osificación óptima
BR112017021021A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112015021999A8 (pt) inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
GT201700035A (es) Compuestos aminopirimidinilo como inhibidores de jak
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
GT201400034A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
BR112015032595A2 (pt) inibidores de ido
CL2015003355A1 (es) Derivados del bipirazol como inhibidores jak
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112017015864A2 (pt) compostos e métodos para modular a expressão de tmprss6
UY37018A (es) Inhibidores bicíclicos de pad4
ECSP14028612A (es) Compuestos de microarn y metodos de modulacion de la actividad de mir-21
CR20160321A (es) Modulares de tetrahidropiridopirazinas de gpr6
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
BR112016029076A8 (pt) Modulação de atividade de complemento
PH12014502513A1 (en) Nampt inhibitors
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
EA201692143A1 (ru) Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
MX2014013752A (es) Inhibidores de nampt.
CO2018013240A2 (es) Oligonucleótidos antisentido para modular la expresión de htra1
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
UY36448A (es) COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC
UY37017A (es) Inhibidores aza-bencimidazol de pad4
WO2018039475A8 (en) Use of pridopidine for treating dystonias